Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

Journal of hepatology - 1 May 2008

Sung Joseph J Y, Lai Jak-Yiu, Zeuzem Stefan, Chow Wan Chen, Heathcote E Jenny, Perrillo Robert P, Brosgart Carol L, Woessner Mary A, Scott Susan A, Gray D Fraser, Gardner Stephen D

Abstract excerpt

BACKGROUND/AIMS: We aimed to evaluate nucleoside/nucleotide combination therapy in treatment-naïve HBeAg-positive patients with chronic hepatitis B (CHB). METHODS: One hundred and fifteen HBeAg-positive patients received lamivudine 100 mg daily plus placebo (monotherapy) or lamivudine 100 mg plus adefovir dipoxil 10 mg daily (combination therapy) for 104 weeks in a randomized double-blind study. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Alanine Transaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis B

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Lamivudine

Share to Organophosphonates

Source

Identifiers

PMID: 18329126
DOI: 10.1016/j.jhep.2007.12.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.PMID 18329126Read ↗

[Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively].Semantic proximity Read ↗

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.Semantic proximity Read ↗

Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.Semantic proximity Read ↗

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.Semantic proximity Read ↗

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.Semantic proximity Read ↗

Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.Semantic proximity Read ↗

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.Semantic proximity Read ↗

Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.Semantic proximity Read ↗

Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.Semantic proximity Read ↗

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.